Indacaterol/glycopyrronium: a dual bronchodilator for COPD
• Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Banerji, Donald [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018 |
|---|
| Umfang: |
8 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Triazolopyridazine LRRK2 kinase inhibitors - 2013, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:23 ; year:2018 ; number:1 ; pages:196-203 ; extent:8 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.drudis.2017.10.015 |
|---|
| Katalog-ID: |
ELV041661869 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV041661869 | ||
| 003 | DE-627 | ||
| 005 | 20230624090701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2017.10.015 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000101A.pica |
| 035 | |a (DE-627)ELV041661869 | ||
| 035 | |a (ELSEVIER)S1359-6446(17)30296-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 630 |q VZ |
| 084 | |a 22 |2 ssgn | ||
| 084 | |a 46.00 |2 bkl | ||
| 100 | 1 | |a Banerji, Donald |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Indacaterol/glycopyrronium: a dual bronchodilator for COPD |
| 264 | 1 | |c 2018 | |
| 300 | |a 8 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. | ||
| 700 | 1 | |a Fogel, Robert |4 oth | |
| 700 | 1 | |a Patalano, Francesco |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Triazolopyridazine LRRK2 kinase inhibitors |d 2013 |g Amsterdam [u.a.] |w (DE-627)ELV011759550 |
| 773 | 1 | 8 | |g volume:23 |g year:2018 |g number:1 |g pages:196-203 |g extent:8 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.drudis.2017.10.015 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 46.00 |j Tiermedizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2018 |e 1 |h 196-203 |g 8 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
d b db |
|---|---|
| matchkey_str |
banerjidonaldfogelrobertpatalanofrancesc:2018----:naaeogyoyrnuaulrnh |
| hierarchy_sort_str |
2018 |
| bklnumber |
46.00 |
| publishDate |
2018 |
| allfields |
10.1016/j.drudis.2017.10.015 doi GBV00000000000101A.pica (DE-627)ELV041661869 (ELSEVIER)S1359-6446(17)30296-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Banerji, Donald verfasserin aut Indacaterol/glycopyrronium: a dual bronchodilator for COPD 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. Fogel, Robert oth Patalano, Francesco oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:23 year:2018 number:1 pages:196-203 extent:8 https://doi.org/10.1016/j.drudis.2017.10.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2018 1 196-203 8 045F 610 |
| spelling |
10.1016/j.drudis.2017.10.015 doi GBV00000000000101A.pica (DE-627)ELV041661869 (ELSEVIER)S1359-6446(17)30296-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Banerji, Donald verfasserin aut Indacaterol/glycopyrronium: a dual bronchodilator for COPD 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. Fogel, Robert oth Patalano, Francesco oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:23 year:2018 number:1 pages:196-203 extent:8 https://doi.org/10.1016/j.drudis.2017.10.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2018 1 196-203 8 045F 610 |
| allfields_unstemmed |
10.1016/j.drudis.2017.10.015 doi GBV00000000000101A.pica (DE-627)ELV041661869 (ELSEVIER)S1359-6446(17)30296-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Banerji, Donald verfasserin aut Indacaterol/glycopyrronium: a dual bronchodilator for COPD 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. Fogel, Robert oth Patalano, Francesco oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:23 year:2018 number:1 pages:196-203 extent:8 https://doi.org/10.1016/j.drudis.2017.10.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2018 1 196-203 8 045F 610 |
| allfieldsGer |
10.1016/j.drudis.2017.10.015 doi GBV00000000000101A.pica (DE-627)ELV041661869 (ELSEVIER)S1359-6446(17)30296-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Banerji, Donald verfasserin aut Indacaterol/glycopyrronium: a dual bronchodilator for COPD 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. Fogel, Robert oth Patalano, Francesco oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:23 year:2018 number:1 pages:196-203 extent:8 https://doi.org/10.1016/j.drudis.2017.10.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2018 1 196-203 8 045F 610 |
| allfieldsSound |
10.1016/j.drudis.2017.10.015 doi GBV00000000000101A.pica (DE-627)ELV041661869 (ELSEVIER)S1359-6446(17)30296-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Banerji, Donald verfasserin aut Indacaterol/glycopyrronium: a dual bronchodilator for COPD 2018 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. Fogel, Robert oth Patalano, Francesco oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:23 year:2018 number:1 pages:196-203 extent:8 https://doi.org/10.1016/j.drudis.2017.10.015 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 23 2018 1 196-203 8 045F 610 |
| language |
English |
| source |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:23 year:2018 number:1 pages:196-203 extent:8 |
| sourceStr |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:23 year:2018 number:1 pages:196-203 extent:8 |
| format_phy_str_mv |
Article |
| bklname |
Tiermedizin: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| authorswithroles_txt_mv |
Banerji, Donald @@aut@@ Fogel, Robert @@oth@@ Patalano, Francesco @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011759550 |
| dewey-sort |
3610 |
| id |
ELV041661869 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041661869</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624090701.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2017.10.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000101A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041661869</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(17)30296-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Banerji, Donald</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Indacaterol/glycopyrronium: a dual bronchodilator for COPD</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fogel, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patalano, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:196-203</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2017.10.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">196-203</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Banerji, Donald |
| spellingShingle |
Banerji, Donald ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 Indacaterol/glycopyrronium: a dual bronchodilator for COPD |
| authorStr |
Banerji, Donald |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011759550 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences 630 - Agriculture & related technologies |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Indacaterol/glycopyrronium: a dual bronchodilator for COPD |
| topic |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| topic_unstemmed |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| topic_browse |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r f rf f p fp |
| hierarchy_parent_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| hierarchy_parent_id |
ELV011759550 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry 630 - Agriculture |
| hierarchy_top_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011759550 |
| title |
Indacaterol/glycopyrronium: a dual bronchodilator for COPD |
| ctrlnum |
(DE-627)ELV041661869 (ELSEVIER)S1359-6446(17)30296-9 |
| title_full |
Indacaterol/glycopyrronium: a dual bronchodilator for COPD |
| author_sort |
Banerji, Donald |
| journal |
Triazolopyridazine LRRK2 kinase inhibitors |
| journalStr |
Triazolopyridazine LRRK2 kinase inhibitors |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
196 |
| author_browse |
Banerji, Donald |
| container_volume |
23 |
| physical |
8 |
| class |
610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Banerji, Donald |
| doi_str_mv |
10.1016/j.drudis.2017.10.015 |
| dewey-full |
610 540 630 |
| title_sort |
indacaterol/glycopyrronium: a dual bronchodilator for copd |
| title_auth |
Indacaterol/glycopyrronium: a dual bronchodilator for COPD |
| abstract |
• Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. |
| abstractGer |
• Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. |
| abstract_unstemmed |
• Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
1 |
| title_short |
Indacaterol/glycopyrronium: a dual bronchodilator for COPD |
| url |
https://doi.org/10.1016/j.drudis.2017.10.015 |
| remote_bool |
true |
| author2 |
Fogel, Robert Patalano, Francesco |
| author2Str |
Fogel, Robert Patalano, Francesco |
| ppnlink |
ELV011759550 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.drudis.2017.10.015 |
| up_date |
2024-07-06T20:44:10.225Z |
| _version_ |
1803863877459378176 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV041661869</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624090701.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2017.10.015</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000101A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV041661869</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(17)30296-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Banerji, Donald</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Indacaterol/glycopyrronium: a dual bronchodilator for COPD</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Development of IND/GLY was driven by a need to improve standards in COPD care • The Phase 3 IGNITE program showed that IND/GLY is effective and well-tolerated • The program helped elucidate the place for LABA/LAMA FDCs in treatment guidelines • Availability of IND/GLY has helped optimise clinical practices in COPD management • Further research may confirm how dual bronchodilation can maximise patient care.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fogel, Robert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Patalano, Francesco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:23</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:196-203</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2017.10.015</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">23</subfield><subfield code="j">2018</subfield><subfield code="e">1</subfield><subfield code="h">196-203</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401063 |